TNF-α promoter polymorphisms and susceptibility to human papiflomavirus 16-associated cervical cancer

Journal of Infectious Diseases

Volumn 191, Issue 6, 2005, Pages 969-976

  Deshpande, Alina ^a   Nolan, John P ^a,c   White, P Scott ^a   Valdez, Yolanda E ^a   Hunt, William C ^b   Peyton, Cheri L ^b   Wheeler, Cosette M ^b  

^a LOS ALAMOS NATIONAL LABORATORY   (United States)

^b UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^c LA JOLLA BIOENGINEERING INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; FLOW CYTOMETRY; GENETIC TRANSCRIPTION; GENOTYPE; HAPLOTYPE; HISPANIC; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROMOTER REGION; SEQUENCE ANALYSIS; SEX ROLE; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; UTERINE CERVIX CANCER; VIRUS INFECTION;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HISPANIC AMERICANS; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS); TUMOR NECROSIS FACTOR-ALPHA; UTERINE CERVICAL NEOPLASMS;

EID: 14844333092     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/427826     Document Type: Article

References (63)

1. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer incidence in five continents: volume VIII. Lyon: IARC Scientific, 1997.
2. Parkin DM, Pisani P, Ferlay I. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999; 80:827-41.
3. Ho GY, Burk RD, Klein S, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Nat Cancer Inst 1995; 87:1365-71.
4. Malejczyk J, Malejczyk M, Kock A, et al. Autocrine growth limitation of human papillomavirus type-16 harboring keratinocytes by constitutively released tumor necrosis factor-α. J Immunol 1992; 149:2702-8.
5. Bequet-Romero M, Lopez-Ocejo O. Angiogenesis modulators expression in culture cell lines positives for HPV-16 oncoproteins. Biochem Biophys Res Commun 2000; 277:55-61.
6. Tjiong MY, van der Vange N, ter Schegget JS, Burger MPM, ten Kate FWJ, Out TA. Cytokines in cervicovaginal washing fluid from patients with cervical neoplasia. Cytokine 2001; 14:357-60.
7. Basile JR, Zacny V, Munger K. The cytokines tumor necrosis factor-α (TNF-α) and TNF-related apoptosis-inducing ligand differentially modulate proliferation and apoptotic pathways in human keratinocytes expressing the human papillomavirus-16 E7 oncoprotein. J Biol Chem 2001; 276:22522-8.
8. Suk K, Chang I, Kim YH, et al. Interferon γ (IFNγ) and tumor necrosis factor α synergism in ME-180 cervical cancer cell apoptosis and necrosis. J Biol Chem 2001; 276:13153-9.
9. Malejczyk J, Majewski S, Jablonska S. Cellular immunity in cutaneous and genital HPV infections. Clin Dermatol 1997; 15:261-74.
10. Vieira KB, Goldstein DJ, Villa LL. Tumor necrosis factor α interferes with the cell cycle of normal and papillomavirus-immortalized human keratinocytes. Cancer Res 1996; 56:2452-7.
11. Kyo S, Inoue M, Hayasaka N, et al. Regulation of early gene expression of human papillomavirus type 16 by inflammatory cytokines. Virology 1994; 200:130-9.
12. Hallermalm K, Seki K, Wei CH, et al. Tumor necrosis factor-α induces coordinated changes in major histocompatibility class I presentation pathway, resulting in increased stability of class I complexes at the cell surface. Blood 2001; 98:1108-15.
13. Hajeer AH, Hutchinson IV. TNF-α gene polymorphism: clinical and biological implications. Microsc Res Tech 2000; 50:216-28.
14. Jacob CO, Lee SK, Strassmann G. Mutational analysis of TNF-α gene reveals a regulatory role for the 3′-untranslated region in the genetic predisposition to lupus-like autoimmune disease. J Immunol 1996; 156:3043-50.
15. Peschon JJ, Torrance DS, Stocking KL, et al. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J Immunol 1998; 160:943-52.
16. Hajeer AH, Hutchinson IV. Influence of TNFα gene polymorphisms on TNFα production and disease. Hum Immunol 2001; 62:1191-9.
17. Kroeger KM, Carville KS, Abraham LJ. The - 308 tumor necrosis factor-α promoter polymorphism effects transcription. Mol Immunol 1997; 34:391-9.
18. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor α promoter on transcriptional activation. Proc Natl Acad Sci USA 1997; 94:3195-9.
19. Knight JC, Udalova I, Hill AVS, et al. A polymorphism that affects OCT-1 binding to the TNF promoter region is associated with severe malaria. Nat Genet 1999; 22:145-50.
20. Hohjoh H, Tokunaga K. Allele-specific binding of the ubiquitous transcription factor OCT-1 to the functional single nucleotide polymorphism (SNP) sites in the tumor necrosis factor-alpha gene (TNFA) promoter. Genes Immun 2001; 2:105-9.
21. Hohler T, Kruger A, Gerken G, Schneider PM, ZumBuschenfelde KHM, Rittner C. A tumour necrosis factor-alpha (TNF-α) promoter polymorphism is associated with chronic hepatitis B infection. Clin Exp Immunol 1998; 111:579-82.
22. Loke H, Bethell D, Day N, White NJ, Hill AVS. A TNF promoter variant, HLA, and dengue in Vietnam. Hum Immunol 1996; 47:124.
23. Wang SS, Wheeler CM, Hildesheim A, et al. Human leukocyte antigen class I and II alleles and risk of cervical neoplasia: results from a population-based study in Costa Rica. J Infect Dis 2001; 184:1310-4.
24. Cuzick J, Terry G, Ho L, et al. Association between high-risk HPV types, HLA DRB1* and DQB1* alleles and cervical cancer in British women. Br J Cancer 2000; 82:1348-52.
25. Maciag PC, Schlecht NF, Souza PSA, Franco EL, Villa LL, Petzl-Erler ML. Major histocompatibility complex class II polymorphisms and risk of cervical cancer and human papillomavirus infection in Brazilian women. Cancer Epidemiol Biomarkers Prev 2000; 9:1183-91.
26. Madeleine MM, Brumback B, Cushing-Haugen KL, et. al. Human leukocyte antigen class II and cervical cancer risk: a population-based study. J Infect Dis 2002; 186:1565-74.
27. Ghaderi M, Nikitina L, Peacock CS, et al. Tumor necrosis factor a-11 and DR15-DQ6 (B*0602) haplotype increase the risk for cervical intraepithelial neoplasia in human papillomavirus 16 seropositive women in northern Sweden. Cancer Epidemiol Biomarkers Prev 2000; 9:1067-70.
28. Jang WH, Yang YI, Yea SS, et al. The -238 tumor necrosis factor-α promoter polymorphism is associated with decreased susceptibility to cancers. Cancer Letters 2001; 166:41-6.
29. Calhoun ES, McGovern RM, Janney CA, et al. Host genetic polymorphism analysis in cervical cancer. Clin Chem 2002; 48:1218-24.
30. Gostout BS, Poland GA, Calhoun ES, et al. TAP1, TAP2, and HLA-DR2 alleles are predictors of cervical cancer risk. Gynecol Oncol 2003; 88:326-32.
31. Kaderali L, Deshpande A, Nolan JP, White PS. Primer design for multiplexed genotyping. Nucleic Acids Res 2003; 31:1796-802.
32. Ewing B, Hillier L, Wendl MC, Green P. Base-calling of automated sequencer traces using phred. I. Accuracy assessment. Genome Res 1998; 8:175-85.
33. Ewing B, Green P. Base-calling of automated sequencer traces using phred. II. Error probabilities. Genome Res 1998; 8:186-94.
34. Nickerson DA, Tobe VO, Taylor SL. PolyPhred: automating the detection and genotyping of single nucleotide substitutions using fluorescence-based resequencing. Nucleic Acids Res 1997; 25:2745-51.
35. Niu TH, Qin ZHS, Xu XP, Liu JS. Bayesian haplotype inference for multiple linked single-nucleotide polymorphisms. Am J Hum Genet 2002; 70:157-69.
36. Greer CE, Wheeler CM, Manos MM. Sample preparation and PCR amplification from paraffin-embedded tissues. PCR Methods Appl 1994; 3:S113-22.
37. Peyton CL, Gravitt PE, Hunt WC, et al. Determinants of genital human papillomavirus detection in a US population. J Infect Dis 2001; 183:1554-64.
38. Gravitt PE, Peyton CL, Apple RJ, Wheeler CM. Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method. J Clin Microbiol 1998; 36:3020-7.
39. Cai H, White PS, Torney D, et al. Flow cytometry-based minisequencing: a new platform for high-throughput single-nucleotide polymorphism scoring. Genomics 2000; 66:135-43.
40. Allen RD. Polymorphism of the human TNF-alpha promoter - random variation or functional diversity? Mol Immunol 1999; 36:1017-27.
41. Fredman D, Siegfried M, Yuan YP, Bork P, Lehväslaiho H, Brookes AJ. HGVbase: a human sequence variation database emphasizing data quality and a broad spectrum of data sources. Nucleic Acids Res 2002; 30:387-91.
42. Andreakos ET, Foxwell BM, Brennan FM, Maini RN, Feldmann M. Cytokines and anti-cytokine biologicals in autoimmunity: present and future. Cytokine Growth Factor Rev 2002; 13:299-313.
43. Pfeffer K. Biological functions of tumor necrosis factor cytokines and their receptors. Cytokine Growth Factor Rev 2003; 14:185-91.
44. Ljunggren G, Anderson DJ. Cytokine-induced modulation of MHC class-I and class-II molecules on human cervical epithelial cells. J Reprod Immunol 1998; 38:123-38.
45. Skoog T, van't Hooft FM, Kallin B, et al. A common functional polymorphism (C→A substitution at position - 863) in the promoter region of the tumour necrosis factor-α (TNF-α) gene associated with reduced circulating levels of TNF-α. Hum Molec Genet 1999; 8:1443-9.
46. Haukim N, Bidwell J, Smith A, et. al. Cytokine gene polymorphism in human disease: on-line databases, supplement 2. Genes Immun 2002; 3:313-30.
47. McGuire W, Hill AVS, Allsop CEM, Greenwood BM, Kwiatkowski D. Variation in the TNF-α promoter region associated with susceptibility to cerebral malaria. Nature 1994; 371:508-11.
48. Nadel S, Newport MJ, Booy R, Levin M. Variation in the tumor necrosis factor-α gene promoter region may be associated with death from meningococcal disease. J Infect Dis 1996; 174:878-80.
49. Sullivan KE, Wooten C, Schmeckpeper BJ, Goldman D, Petri MA. A promoter polymorphism of tumor necrosis factor α associated with systemic lupus erythematosus in African-Americans. Arthritis Rheum 1997; 40:2207-11.
50. Uglialoro AM, Turbay D, Pesavento PA, et al. Identification of three new single nucleotide polymorphisms in the human tumor necrosis factor-α gene promoter. Tissue Antigens 1998; 52:359-67.
51. Udalova IA, Richardson A, Denys A, et al. Functional consequences of a polymorphism affecting NF-κB p50-p50 binding to the TNF promoter region. Molec Cell Biol 2000; 20:9113-9.
52. Hill AVS. Immunogenetics and genomics. Lancet 2001; 357:2037-41.
53. Hildesheim A, Wang SS. Host and viral genetics and risk of cervical cancer: a review. Virus Res 2002; 89:229-40.
54. Cullen M, Perfetto SP, Klitz W, Nelson G, Carrington M. High-resolution patterns of meiotic recombination across the human major histocompatibility complex. Am J Hum Genet 2002; 71:759-76.
55. Brinkman BM, Huizinga TW, Kurba SS, et al. Tumour necrosis factor α gene polymorphisms in rheumatoid arthritis: association with susceptibility to, or severity of, disease? Br J Rheumatol 1997; 36:516-21.
56. Rood MJ, van Krugten MV, Zanelli E, et al. TNF-308A and HLADR3 alleles contribute independently to susceptibility to systemic lupus erythematosus. Arthritis Rheum 2000; 43:129-34.
57. Yoon JK, Hyo-Suk L, Jung-Hwan Y, et al. Association of TNF-α promoter polymorphisms with the clearance of hepatitis B virus infection. Hum Molec Genet 2003; 12:2541-6.
58. Juszczynski P, Kalinka E, Bienvenu J, et al. Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome. Blood 2002; 100:3037-40.
59. Higuchi T, Seki N, Kamizono S, et al. Polymorphisms of the 5′-flanking region of the human tumor necrosis factor (TNF)-α gene in Japanese. Tissue Antigens 1998; 51:605-12.
60. Matsushita M, Tsuchiya N, Nakayama T, et al. Allele typing of human TNFA 5′-flanking region using polymerase chain reaction-preferential homoduplex formation assay (PCR-PHFA): linkage disequilibrium with HLA class I and class II genes in Japanese. Tissue Antigens 1999; 54:478-34.
61. Jongeneel CV, Brinat L, Udalova IA, Sevin A, Nedospasov SA, Cambon-Thomsen A. Extensive genetic polymorphism in the human tumor necrosis factor region and relation to extended HLA haplotypes. Proc Natl Acad Sci USA 1991; 88:9717-21.
62. Waldron-Lynch F, Adams C, Amos C, et al. Tumor necrosis factor 5′ promoter single nucleotide polymorphisms influence susceptibility to rheumatoid arthritis (RA) in immunogenetically defined multiplex RA families. Genes Immun 2001; 2:82-7.
63. Posch PE, Cruz I, Bradshaw D, Medhekar BA. Novel polymorphisms and the definition of promoter "alleles" of the tumor necrosis factor and lymphotoxin α loci: inclusion in HLA haplotypes. Genes Immun 2003; 4:547-58.